SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 234 filers reported holding SAGE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $286,397 | +22.1% | 6,091 | +9.0% | 0.00% | 0.0% |
| Q1 2023 | $234,513 | +1703.9% | 5,589 | +1290.3% | 0.00% | – |
| Q2 2022 | $13,000 | -35.0% | 402 | -32.8% | 0.00% | – |
| Q1 2022 | $20,000 | +100.0% | 598 | +160.0% | 0.00% | – |
| Q4 2021 | $10,000 | -47.4% | 230 | -47.6% | 0.00% | – |
| Q3 2021 | $19,000 | -36.7% | 439 | -16.9% | 0.00% | – |
| Q2 2021 | $30,000 | -23.1% | 528 | +2.3% | 0.00% | – |
| Q1 2021 | $39,000 | -50.0% | 516 | -42.9% | 0.00% | -100.0% |
| Q4 2020 | $78,000 | +1014.3% | 903 | +692.1% | 0.00% | – |
| Q3 2020 | $7,000 | +40.0% | 114 | 0.0% | 0.00% | – |
| Q2 2020 | $5,000 | +400.0% | 114 | +2750.0% | 0.00% | – |
| Q2 2018 | $1,000 | -50.0% | 4 | -69.2% | 0.00% | – |
| Q1 2018 | $2,000 | – | 13 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |